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Abstract
Background: Cancer associated fibroblasts (CAF) play important roles in tumor growth that involves inflammation
and epithelial cell differentiation. Early studies suggested that estrogen receptor alpha (ERα) was expressed in
stromal cells in normal prostates and prostate cancer (PCa), but the detailed functions of stromal ERα in the PCa
remain to be further elucidated.
Methods: Migration and invasion assays demonstrated the presence of high levels of ERα in CAF cells (CAF.ERα(+))
suppressed PCa invasion via influencing the infiltration of tumor associated macrophages. ERα decreased CAF CCL5
secretion via suppressing the CCL5 promoter activity was examined by luciferase assay. ERα decreased CCL5 and
IL-6 expression in conditioned media that was collected from CAF cell only or CAF cell co-cultured with
macrophages as measured by ELISA assay.
Results: Both in vitro and in vivo studies demonstrated CAF.ERα(+) led to a reduced macrophage migration toward
PCa via inhibiting CAF cells secreted chemokine CCL5. This CAF.ERα(+) suppressed macrophage infiltration affected
the neighboring PCa cells invasion and the reduced invasiveness of PCa cells are at least partly due to reduced IL6
expression in the macrophages and CAF.
Conclusion: Our data suggest that CAF ERα could be applied as a prognostic marker to predict cancer progression,
and targeting CCL5 and IL6 may be applied as an alternative therapeutic approach to reduce M2 type
macrophages and PCa invasion in PCa patients with low or little ERα expression in CAF cells.
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Background
Prostate cancer (PCa) is the most frequently diagnosed
cancer and second leading cause of cancer death in men
in the United States [1]. PCa is a chronic type of tumor
that requires a long time for small lesions to become
clinically manifested compared to some other cancers
[2]. Inflammation has been thought to be one of the key
pathogenic factors for PCa and there is an association
between chronic inflammation and increased prevalence
of PCa [3–6]. Furthermore, tumor associated macro-
phages (TAM) form a major component of the inflam-
matory infiltrates in both primary and secondary tumors
[7] and can release growth factors, cytokines and chemo-
kines to regulate tumor growth and invasion [8]. How-
ever, the detailed mechanisms how the interactions
among stromal cells, TAM, and PCa cells could influ-
ence the growth and metastasis of PCa remain to be fur-
ther elucidated.
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An earlier study suggested that cancer associated fi-
broblasts (CAF) may play important roles to influence
PCa progression and invasion [9]. In the prostate tumor
microenvironment (TME), PCa epithelial cells can pro-
duce some growth factors, such as TGF-β, PDGF and
FGF, to influence/activate peripheral stromal cells that
result in transformation of normal fibroblasts into CAF.
Subsequently, CAF can then increase in population
through transforming from normal fibroblasts [10], dif-
ferentiation from bone marrow-derived mesenchymal
stem cells [11] or by epithelial to mesenchymal transi-
tion (EMT). The important functions of CAF include
the regulation of deposition of extracellular matrix
(ECM), epithelial differentiation, tumor inflammation,
and wound healing [12]. Ezer et al. demonstrated that
CAF could mediate inflammation and angiogenesis by
recruiting macrophages to stimulate angiogenesis, which
may then promote tumor growth [13].
The existence of aromatase (to convert testosterone to
estrogen) [14] and the finding of an increase in
estrogen-to-androgen ratio in aging men [15] indicated
that estrogens, in addition to androgens, could play im-
portant roles in PCa initiation and progression. Animal
studies also demonstrated that 100 % of rats being
treated with 17β-estradiol (E2) plus testosterone for
around 44 weeks had prostatic adenocarcinomas [16].
Estrogen action is mainly mediated through its specific
nuclear receptors that regulate transcription of target
genes via binding to the estrogen response element
(ERE) or non-ERE mediated transactivation, as well as
non-genomic regulations [17]. There are two major
types of estrogen receptors (ERs), ER alpha (ERα) and
ER beta (ERβ) [18, 19]. The two ER subtypes are struc-
turally similar, consisting of the six common domains
(A–F), but encoded by separate genes (ESR1 and ESR2).
Immunostaining indicated that ERα positive [ERα(+)]
staining was present in normal prostate stromal cells nu-
clei [20]. The function of stromal ERα, however, remains
largely unknown.
It has been well demonstrated that cancer related in-
flammation promotes cancer cells proliferation, migra-
tion and invasion through several pathways, including
signal transduction activation, cytokines secretion and
immune cells infiltration [21]. The TAM, M2 type, are
the major players that link tumor related inflammation
and tumor progression [22]. A variety of chemokines,
like CCL2 and CCL5, have been detected in neoplastic
tissues and associated with tumor associated immune
cells formation and recruitment [23].
Using the in vitro co-culture system and in vivo mouse
models, we studied CAF ERα roles in PCa invasion and
found CAF ERα could inhibit PCa metastasis via sup-
pression of macrophage infiltration and M2 type macro-
phages formation. This CAF.ERα(+) → macrophages →
PCa invasion pathway involves the modulation of CAF
CCL5 and macrophages IL6 gene expressions. This find-
ing supports the clinical observation that PCa patients
with stromal ERα have better PSA free survival rates [24].
Results
ERα in CAFs suppressed macrophage infiltration
Early reports showed that ERα in stromal cells could affect
the prostate development [25, 26]. Another report showed
that E2 plus testosterone treatment could stimulate the
PCa initiation [27], however, the role of stromal ERα in
the later stages of PCa progression and how it may affect
immune cell infiltration and PCa metastasis is not well
studied. Although the positive expression of ERα in the
CAF is lower than in the benign component of human
PCa tissues [28], the clinical correlation has been identi-
fied and one study showed patients with CAF.ERα(+) ex-
pression have better PSA free recurrence survival rate
[24]. We isolated CAF from TRAMP mice prostate tu-
mors, immortalized them by SV40 large T-antigen, and
then studied how ERα in CAF cells may affect the infiltrat-
ing macrophages. Using a transwell system of adding
macrophage RAW-264.7 cells on the insert wells and
seeding CAF.ERα(+) or CAF.ERα(−) cells in the bottom
chambers, we found chambers seeded with CAF.ERα(+)
had less macrophages infiltrated than with CAF.ERα(−)
cells (Fig. 1a). Similar results were obtained when we re-
placed mouse macrophage RAW-264.7 cells with B6
mouse primary macrophages (Mφ) (Fig. 1b). We also
compared macrophages recruitment between CAF.ERα(−)
and CAF.ERα(+) with/without E2 treatment. Our results
indicated that E2 treatment can further reduce
CAF.ERα(+) diminished macrophage recruitment and
treatment with ICI182,780 can reverse E2 and ERα re-
duced macrophage infiltration (Fig. 1c).
Together, results from Fig. 1 suggest that CAF with
ERα expression could reduce macrophage population in
the PCa microenvironment.
Infiltrating macrophages enhance PCa invasion
To further study the consequences of altered infiltrating
macrophages on PCa invasion, we co-cultured mouse
CAF.ERα(+) or CAF.ERα(−) cells with mouse macro-
phages and then collected the conditioned media (CM)
to assay the influence on the invasiveness of mouse PCa
cells (TRAMP-C1). As shown in Fig. 2a, the CM from
co-culture of CAF.ERα(+) and mouse RAW264.7 cells led
a lower TRAMP-C1 cells invasion as compared to CM
from co-culture of CAF.ERα(−) and RAW-264.7 cells.
Similar results were obtained when we replaced TRAMP-
C1 cells with human PCa cells CWR22Rv-1 (22Rv1),
C4-2, or PC-3 cells (Fig. 2a). Furthermore, replacing
mouse macrophage RAW-264.7 cells with B6 primary
macrophages (Mφ) also showed similar results (Fig. 2b).
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We also evaluated ERα activity by E2 and ICI182,780
to confirm stromal ERα role in PCa invasion. We co-
cultured CAF.ERα(−)/macrophages, CAF.ERα(+)/mac-
rophages with/without ICI182,780 and/or E2 treatment
for 2 days. CMs were collected to induce CWR22Rv-1
cells invasion. Our data showed E2 treatment can sup-
press PCa invasion but adding ICI 182,780 can partially
reverse this decreased invasion (Fig. 2c). We also observed
similar results in C4-2 cells (Additional file 1: Figure S1).
To mimic the in vivo tumor micro-environment, we ap-
plied the 3D invasion assay system to confirm the out-
comes from the transwell invasion assay. In the 3D assay,
the formation of acini-like structures counts as an indica-
tor for invasion [29]. CM collected from CAF.ERα(−)/
macrophages co-culture increased the CWR22Rv-1 cell
formation of acini-like structures as compared to CM
from CAF.ERα(+)/macrophages co-culture (Additional file
2: Figure S2A). We also found decreased laminin 5 (an in-
dicator of increased invasion) in PCa cells cultured with
the CM from the CAF.ERα(−)/macrophages as compared
to CM from CAF.ERα(+)/macrophages (Additional file 2:
Figure S2B). Importantly, the expression of the key inva-
sion marker, MMP9, was 2 fold higher in CWR22Rv1 cells
treated with CM of CAF.ERα(−)/RAW264.7 co-culture
than those treated with CM from CAF.ERα(+)/RAW264.7
co-culture (Additional file 2: Figure S2C) in this 3D inva-
sion system.
Together, results from Fig. 2 and Additional file 2: Figure
S2 using different invasion assays with different macro-
phages and PCa cells all suggested that ERα in CAF could
suppress PCa invasion at least partly via suppressing the
infiltrating macrophages.
CAF.ERα(+) suppresses PCa invasion via reduced
macrophage infiltration in the in vivo mouse PCa model
To confirm the above in vitro results in the in vivo animal
model, we orthotopically co-implanted CAF.ERα(+) or
CAF.ERα(−) plus CWR22Rv-1 cells. CWR22Rv1 cells were
Fig. 1 ERα expression in CAF reduced the macrophage (Mφ) migration. a and b CAF ERα reduces the migration of macrophages. CAF.ERα(+) or
ERα(−) cells were cultured in 24-well plates for 24 h. We then added macrophages in inserted upper transwells (5 μm pore size) for 24 h and then
compared macrophages migration rate toward CAF.ERα(−) vs. CAF.ERα(+) cells. c 17β-estradiol (E2) treatment can reduce macrophage migration
in CAF.ERα(+) cells and ICI182,780 (ICI) treatment can reverse E2 effects. CAF.ERα(−) or CAF.ERα(+) cells were first cultured in media with 5 % CD
FBS for 2 days, then seeded in 24-well plates, and incubated with vehicle, E2 (10 nM) or/and ICI (10 μM) for 24 h. We then added macrophages
into inserted upper transwells (5 μm pore size) for 24 h and compared macrophage migration rates toward CAF.ERα(−) vs. CAF.ERα(+). Migrated
macrophages were fixed and stained by 1 % toluidine blue in PBS. Quantifications are in right panels. *, P < 0.05 vs. CAF.ERα(−) cells
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stably transfected with firefly luciferase (22Rv1-Luc) to
monitor tumor implantation, growth, and metastasis using
the non-invasive in vivo IVIS imaging system. Twelve
weeks after implantation, tumors were collected from both
primary and metastatic sites (Fig. 3). We compared the in-
filtrated macrophages by IHC staining and found less infil-
trated macrophages, including M1 (F4/80) and M2
(CD206) macrophages [30], in CAF.ERα(+)/22Rv1-Luc
primary tumors than in the CAF.ERα(−)/22Rv1-Luc pri-
mary tumors (Fig. 3a). We carefully examined the tumor
histology, and found that in the co-implants of CAF.ERα(−)
and PCa cells, our data show tumors were big, cells were
more dense, and necrosis could be observed in the central
part of tumor (data not shown). We also found that 4 out
of 7 CAF.ERα(−)/22Rv-1-Luc co-implanted mice and 2 out
of 7 CAF.ERα(+)/22Rv-1-Luc co-implanted mice with
Fig. 2 Effects of CM from co-cultured CAF.ERα(+)/macrophages or CAF.ERα(−) /macrophages (Mφ) on PCa invasion. The carton illustrates the PCa
invasion transwell system. CM was collected from 48 h co-culture of CAF.ERα(+) or CAF.ERα(−) and RAW264.7 (RAW) cells (a) or B6 primary macrophages
(Mφ) (b), co-cultured CM was added to 24-well plates and the PCa cells TRAMP-C1, CWR22Rv-1 (22Rv1), C4-2, or PC-3, were seeded into
inserted transwells pre-coated with matrigel. After 24 to 48 h incubation (TRAMPC-1 and PC-3 for 24 h; CWR22Rv-1 and C4-2 for 48 h),
invaded PCa cells were counted and compared between CM of CAF.ERα(−)/macrophages and CAF.ERα(+)/macrophages. c Estrogen
treatment further triggers CAF.ERα(+) reduced PCa invasion. CAF.ERα(−) or ERα(+) cells were treated with vehicle, E2 (10 nM) or/and ICI
(10 μM) and co-cultured with macrophages for 48 h. CMs were collected and added to 24-well plates and the PCa cells (CWR22Rv-1)
were seeded onto inserted transwells pre-coated with matrigel. After 48 h incubation, invaded PCa cells were counted and compared,
and quantitation data is shown at right. *, P < 0.05 vs. CAF.ERα(−)/macrophages CM treatment group
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enlarged pelvic lymph nodes, but the numbers of enlarged
pelvic lymph nodes were variable in individual mice.
Among those mice positive for enlarged lymph nodes,
the CAF.ERα(−) implanted mice presented larger pel-
vic lymph nodes than the CAF.ERα(+) implanted
group. The length or width of nodes in CAF.ERα(−)
mice were ≥2 mm, but not in those CAF.ERα(+) im-
planted group. Thus, we used 2 mm width or length
to define the malignancy of this metastatic PCa. To
verify the enlarged pelvic lymph nodes were corre-
lated to metastasis, but not inflammation, the pelvic
lymph nodes were IHC stained for presence of lucif-
erase. Importantly, this luciferase staining found fewer
metastatic tumors in pelvic lymph nodes in mice co-
implanted with CAF.ERα(+)/22Rv1.Luc cells (Fig. 3b).
Together, results from Fig. 3 suggest that CAF.ERα(+)
may suppress PCa invasion at least partly via altering
the macrophage infiltration into PCa in the in vivo
mouse model.
Mechanism dissection how CAF ERα(+) suppresses
macrophage infiltration
To dissect the molecular mechanism(s) by which
CAF.ERα(+) expression could suppress macrophage infil-
tration, we performed Q-PCR gene expression assays with
several macrophage migration-related chemokines and
cytokines, including the family of the C-C motif chemokine
ligand (CCL) and interleukin (IL) genes. Our results
showed that CCL5 and IL6 gene expression were signifi-
cantly decreased in CAF.ERα(+) cells as compared to those
found in CAF.ERα(−) cells (Fig. 4a). We also co-cultured
macrophages with CAFs to study whether macrophages
can impact ERα functions in CAF cells. The results showed
that compared to CAFs alone, the co-culture of macro-
phages with CAFs resulted in increased CCL5 and
IL6 expression in CAF cells. Consistently, higher ERα
expression in CAF decreased CCL5 and IL6 in CAF
cells while comparing CAF.ERα(+)/macrophages vs.
CAF.ERα(−)/macrophages group (Additional file 3:
Figure S3). The IL6 neutralizing antibody did not
affect the CAF regulated macrophage migration/infil-
tration (data not shown). To further confirm CCL5
expression was altered at the protein level, we assayed
CCL5 concentration in culture media using ELISA,
and results indicated that secreted CCL5 protein de-
creased in CAF.ERα(+) media (Fig. 4b).
There are two identified transcription factor binding
sites in the CCL5 promoter region, including binding sites
for NF-κB (−70 to −58) and (−55 to −42), and a SP1/KLF
binding site (−70 to −58). Previous studies showed that
through a non-ERE pathway the ERα could regulate
downstream genes activities, including NF-κB and AP-1
Fig. 3 In vivo tumor model demonstrated CAF ERα reduced macrophages infiltration and PCa cell invasion. Nude mice were orthotopically
implanted with CAF.ERα(+) or CAF.ERα(−) mixed with CWR22Rv1 cells that were stably transfected with firefly luciferase (22Rv1-Luc). a Tumors
were collected 12 weeks after implantation, and macrophage infiltration was examined by IHC staining of F4/80 (M1 macrophage, upper panel)
and CD206 (M2 macrophage, lower panel) [30]. b Pelvic lymph nodes were collected from CAF.ERα(−)/22Rv1-Luc and CAF.ERα(+)/22Rv1-Luc
co-cultured groups to determine metastasis by measuring sizes of lymph nodes. We confirmed, by IHC staining of luciferase, the presence of
22Rv1-Luc cells in the lymph nodes (lower panel). There were seven mice in each group. We defined pelvic lymph nodes as metastatic when the
diameter was over 2 mm (upper panel) *, P < 0.05 vs. CAF.ERα(−)/22Rv1-Luc tumors
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[31, 32]. We therefore focused on examining whether ERα
could modulate the CCL5 at the transcriptional level by
characterizing the CCL5 promoter (−83 bp) that was con-
structed into a luciferase reporter [33]. Our results showed
that CCL5 luciferase activity is higher in CAF.ERα(−) than
in CAF.ERα(+) cells (Fig. 4c).
We also applied an interruption approach to test if
interrupting the CCL5 signal with CCL5 neutralizing
Fig. 4 ERα reduced the CCL5 expression in CAF cells and consequently decreased macrophages infiltration. a We compared gene profiles of
macrophage attraction related chemokines/cytokines between CAF.ERα(+) and CAF.ERα(−) by QPCR. b The comparison of CCL5 production from
CAF.ERα(+) and CAF.ERα(−) was determined by ELISA through measuring CCL5 concentration in the CM. c CCL5 promoter luciferase activity was
used to determine whether ERα regulates CCL5 expression. CCL5 promoter (−83 bp)-luciferase reporter was transfected into CAF.ERα(+) and
CAF.ERα(−) and cultured in CD-FBS media. 10 nM E2 was added and CCL5 promoter luciferase activity was analyzed using a dual luciferase kit. d
CAF were cultured in bottom wells and incubated with CCL5 neutralizing Ab or IgG (control). After 24 h, macrophages were added into inserted
upper transwells that also contained CCL5 neutralizing Ab or IgG (control). Migrated macrophages were counted and compared to CAF.ERα(−)
with IgG as control. Quantification is in lower panel. e Adding recombinant CCL5 protein reversed CAF.ER(+) reduced macrophage migration. CAF
cells were incubated with recombinant CCL5 protein or control for 24 h, and then macrophages with recombinant CCL5 protein or control were
added to the inserted transwells for migration assay. All migrated macrophages were compared to CAF.ERα(−) with control protein. Quantification
is in lower panel. f CCL5 expression was confirmed by IHC staining in the in vivo mouse PCa tumors co-implanted with/without both CAF/22Rv1-Luc
cells. Arrows show positive CCL5 staining. *, P < 0.05 vs. CAF.ERα(−)/22Rv1 tumors
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antibody may block the effects of CAF.ERα(−) on mac-
rophages infiltration in the co-culture system. Our re-
sults showed the CCL5 neutralizing antibody could
significantly and effectively diminish the CAF.ERα(−)
modulated macrophage infiltration toward CAF with
less effect on CAF.ER(+) modulated infiltration (Fig. 4d,
quantification in lower panel).
Then, we applied another interruption approach
via adding CCL5 recombinant protein to examine
whether the ectopic CCL5 could restore/reverse the
CAF.ERα(+) cells' low-capacity to recruit macro-
phages. Indeed, our results showed adding CCL5 pro-
tein could increase the low-capability of CAF.ERα(+)
cells to attract macrophages, indicating the lower
CCL5 is a key factor that leads to lower macrophages
attraction of CAF.ERα(+) (Fig. 4e). We then examined
the CCL5 expression in mice with in vivo co-implanted
CWR22Rv1-Luc cells with CAF with or without ERα
Fig. 5 CAF.ERα(+) CM treated macrophages have a reduced capability of producing IL6, which could consequently reduce PCa invasion. a We
compared metastatic-related gene profile expressions by QPCR in macrophages after co-culture with CAF.ERα(+) or CAF.ERα(−) cells. Macrophages
were seeded in bottom wells, then CAF.ERα(+) or CAF.ERα(−) cells were seeded onto inserted transwells (0.4 μm) and co-cultured for 24 h. Macrophage
RNA was collected and converted to cDNA. Selected metastatic related genes expressions in macrophage were measured by QPCR, RAW cells in left
panel and Mφ in right panel. b IL6 concentration in CM from CAF/macrophage co-inoculation was measured by ELISA. c IL6 neutralizing antibody
blocks macrophages promoted PCa invasion. The next experiment compared macrophages that were incubated with CM either from CAF.ERα(+) or
CAF.ERα(−). PCa cells (CWR22Rv1, C4-2, or PC3) were seeded onto matrigel pre-coated transwells for 48 h to demonstrate invasive ability. d There is a
lower IL6 staining in CAF.ERα(+)/CWR22Rv1 co-implanted tumors. Arrowheads show the cells that express IL6 protein. Arrows indicate cells positive for
the ERα expression. IL6 expression is reversely correlative to CAF ERα expression using IF staining. *, P < 0.05 vs. CAF.ERα-/ 22Rv1 tumors
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(PCa:CAF = 9:1) and IHC staining of CCL5 data
showed less CCL5 positive signals in CAF.ERα(+) than
in CAF.ERα(−) implanted group (Fig. 4f ).
Together, results from Fig. 4a–f suggest that
CAF.ERα(+) cells have a lower ability to attract macro-
phages due to a lower chemokine CCL5 expression.
Mechanisms of CAF.ERα + suppressed PCa invasion
Next, we examined the molecular mechanism(s) by which
the CAF.ERα(+) affected macrophages could influence
PCa cell invasion. As shown in Fig. 5a, we compared gene
profiles of both RAW-264.7 and B6 primary macrophages
co-cultured with CAF.ERα(+) or CAF.ERα(−) cells, and
found lower IL6 expression in both types of macrophages
after co-culture with CAF.ERα(+) cells. Although TGF-β3
and Wnt 5α expressions increase, yet their mRNA
amounts and expression levels are not as high as IL6. We
therefore set the priority to focus on studying IL6. We fur-
ther examined the altered IL6 expression at the protein
level via ELISA assay and data showed there is less IL6 in
the CM from CAF.ERα(+)/macrophages co-culture sys-
tem. This indicates that CAF.ERα(+) cells have less cap-
ability to stimulate IL-6 secretion from macrophage
RAW-264.7 cells (Fig. 5b). As expected, adding IL6
neutralizing antibody into the CM diminished the
CAF.ERα(−)/macrophage mediated PCa invasion of
CWR22Rv-1, C4-2 and PC3 cells (Fig. 5c). We further
demonstrated CAF.ERα signals-mediated CAF IL-6 reduc-
tion could also impact PCa invasion. We put CM that was
collected from CAF.ERα(−) or CAF.ERα(+) cells with neu-
tralizing IL6 antibody or IgG (control) into bottom wells,
and seeded CWR22Rv1 or C4-2 cells into matrigel-coated
transwell for invasion assay. Our results showed that IL6
neutralizing antibody can decrease CAF-induced PCa cell
invasion (Additional file 4: Figure S4). In vivo evidence
from orthotopically xenografted mouse PCa also confirmed
the above in vitro data showing CAF.ERα(+)/22Rv-1 tu-
mors have less IL6 expression (Fig. 5d). We also confirmed
IL6 and ERα correlation by IF staining of serial section
slides. Our results further indicated there was little IL-6
positive signal when stromal ERα is positively expressed.
Together, results from Fig. 5a–d and Additional file 4:
Figure S4 suggest that CAF.ERα(+) may be able to lower
the production of IL6 in macrophages, consequently re-
duce the macrophages-mediated PCa cell invasion.
Correlative expression of ERα, M2 macrophage, CCL5 and
IL6 in human prostate tumor
To confirm our findings in human prostate tumors, we
further examined the ERα, CD206, CCL5 and IL6 expres-
sions in 14 human PCa tissue specimens by IHC staining.
Our results showed a positive correlation between ERα,
M2 macrophages, CCL5 and IL-6. In high stromal ERα
expression samples, the expression levels of CD206 (M2
macrophage marker), CCL5 and IL6 were higher than in
samples with low stromal ERα expression (Fig. 6). These
results are consistent with our in vitro and in vivo studies.
Discussion
In the TME, chronic inflammation has been proven to
promote cancer progression [34]. Tumor cells can se-
crete chemokines, cytokines and prostaglandins for in-
flammatory cells recruitment in order to sustain the
inflammatory response. Nelson et al. [35] indicated that
inflammation plays an important role in the development
and progression of PCa. The chronic inflammation mainly
occurred in the area directly adjacent to PCa lesions and
induced inflammatory cell infiltration/accumulation. After
immune cells accumulated at the sites, the tumor conse-
quently increased prostate epithelial cells proliferation by
inflammatory oxidants secretion [36]. Furthermore, cancer
related inflammation may affect tumor cell migration, in-
vasion, angiogenesis, etc. Not only epithelial cells, but also
CAF can produce inflammatory factors and affect im-
mune cells recruitment. Among several chemokines,
CCL1, −2, −4, −5, −7, −8, −12, −13, and IL6 might
Fig. 6 M2 macrophages, CCL5 and IL6 expression increase in prostate cancer patients with high stromal ERα expression. To confirm our findings
in human prostate tumors, we also examined ERα, CD206 (M2 macrophage marker), CCL5 and IL6 in human samples by IHC staining. Samples
were provides by Department of Pathology, University of Rochester Medical center
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influence the interaction of inflammation with cancer ma-
lignancy, and CCL2, −3, −5, −7, CXCL12, −14, and IL6
were found to be able to affect the macrophage infiltration
[37]. In our study, we found that expression of ERα in
CAF can reduce the number of infiltrated macrophages
recruited by CAF and PCa cells and subsequently suppress
cancer invasion.
In the cancer initiation stage, epithelial cancer cells
can activate and differentiate fibroblasts into myofibro-
blasts and the activated fibroblasts consequently pro-
mote tumor growth [38, 39]. When tumors progress, the
ratio of cancer cells to CAFs may vary depending on the
stages of the disease. A previous study showed that epi-
thelial and CAF cells were set at different ratios to study
the interaction between fibroblasts and different breast
cancer cells [40]. In a prostate cancer study, Camps et al.
co-injected PC-3 cells with CAFs (PCa:CAF = 10:1; 1 ×
106:1 × 105) into mice and successfully promoted tumor
growth [41]. In another of our studies, we co-injected
CWR22Rv-1 cells and CAFs (22Rv-1:CAFs = 9:1; 9 ×
105:1 × 105) into each lobe of mouse anterior prostates
and tested whether the ERα status in CAFs could pro-
mote or inhibit tumor invasion [24]. When we changed
the PCa:CAF ratio from 9:1 to 5:1, we could also see the
similar effects (data not shown). The data presented in
this study was collected from PCa:CAF at ratio 9:1. In
addition to determining the CAF.ERα-regulated PCa inva-
sion, in another of our projects studying CAF ERα role in
PCa growth, we found the differential roles of
CAF.ERα(+). CAF cells with higher ERα expression could
promote the growth, but inhibit the invasion of PC3,
LNCaP, C4-2 and CWR22Rv-1 cells. The in vivo model
also demonstrated mice co-injected with CWR22Rv-1 and
CAF.ERα(+) cells can develop bigger tumors yet lower
metastasis rates as compared to mice co-injected with
CWR22Rv-1 and CAF.ERα(−) cells (Da and Yeh et al.,
paper in preparation).
CAF have been demonstrated to play important roles
in cancer progression through promoting tumor initi-
ation, growth and invasion via promotion of the extra-
cellular matrix (ECM) remodeling and release of growth
factors and cytokines. CAF are a source of ECM-
degrading proteases such as the MMPs [42], which
might allow cancer cells to escape the primary tumor
site. Our previous study also indicated CAF.ERα(+) sup-
pressed PCa metastasis through decreased Thbs2 and
MMP3 expression [24]. Other studies demonstrated
liver CAF could induce metastases through secreting in-
flammatory factors, like IL6 and MCP-1 [43, 44]. In
addition, CAF have the capability to recruit immune
cells into the tumor region via altering the expression of
IL6, CCL2 [45], or NF-kB signals [13].
Our findings indicated CAF cells expressing ERα have
a lower capability to recruit macrophages. Further
mechanism dissection showed that both CCL5 and IL6 se-
cretions are decreased in CAF.ERα(+), with CCL5 subse-
quently related to macrophage recruitment, but not IL6.
We hypothesized that CCL5 may play a key role for
recruiting the infiltrating macrophages to PCa cells. Robin-
son et al. also demonstrated that CCL5 plays an important
role in attracting macrophage migration and may become a
target for breast cancer therapy [46]. In a breast cancer
murine model, those murine cells treated with Met-CCL5
(receptor antagonist) had a decreased number of infiltrat-
ing macrophages associated with a significantly reduced
tumor size. The development of “anti-macrophages” may
become one option for cancer therapy in the future. M2
type macrophages, one type of inflammatory cells that are
differentiated by IL-4 and IL-13 stimulations, are known as
major mediators linking cancer and inflammation [22, 47].
Recent data showed CAF, through stromal-derived growth
factor-1 secretion, promote M2-type macrophages expres-
sion and PCa progression [48]. We examined M2 macro-
phages related markers expression in macrophages after
CAF CM treatment. Surprising, after co-culture with the
CAF.ERα(+)CM, the macrophages expressed less M2
macrophage markers, including IL-10, Fuzz1 and Ym1,
but not arginase-1 (Additional file 5: Figure S5A), suggest-
ing CAF.ERα(+) may be able to suppress M2-type macro-
phages in the PCa TME. This conclusion is further
supported by the finding of higher IL-4 and IL-13 expres-
sion in CAF.ERα(−) than in CAF.ERα(+) cells (Add-
itional file 5: Figure S5B). This suggests CAF.ERα(+)
cells can release less IL-4 and IL-13 and may induce
less M2-type macrophages than CAF.ERα(−) cells.
In prostate development, using Cre-loxP gene knockout
strategy, reports have shown that ERα plays different roles
in prostate epithelial as well as different types of prostate
stromal cells [26, 49]. In the PCa mouse models, both ERα
knockout [50] and ERα agonist treatment [51] showed mice
with activated ERα can develop high-grade PIN, suggesting
ERα might play important roles in PCa progression. Early
studies indicated the expression of epithelial ERα, but not
stromal ERα, was increased in PCa [52]. Celhay et al. dem-
onstrated stromal ERα may also play an important role in
recurrence of hormone refractory PCa. They compared ERα
expression by IHC in 55 paired patient PCa samples col-
lected before androgen deprivation therapy and after hor-
monal relapse. They found a shorter time to hormonal
relapse was associated with low staining for ERα in stromal
cells and correlated to shorter patient survival rate [53].
Daniels et al. [28] reported that ERα positive rates reduced
in the cancer associated stromal cells compared to the ad-
jacent benign prostate tissue. Although the expression level
of ERα in cancer associated stromal cells is relatively weak,
the intensity of ERα expression in tumor-associated stroma
shows a positive correlation with cancer progression. The
reduced CAF ERα IHC staining by Daniels et al. [28]
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supports our finding that CAF ERα plays a protective role
in cancer invasion. Furthermore, PCa patients with
CAF.ERα(+) expression have a better PSA free recurrence
survival rate [24]. Our data demonstrated stromal ERα can
inhibit PCa invasion through suppressing macrophage in-
filtration into tumor sites and directly decrease cytokine se-
cretion in PCa cells.
Platz et al. indicated chronic inflammation could be an ep-
idemiologic factor for PCa [54], and De Marzo et al. also
linked the PCa progression to inflammation related dietary
factors [4]. Prins et al. [55] demonstrated that estrogen in-
duced inflammation is specifically mediated by epithelial
ERα. The epithelial inflammatory cell infiltrates were ob-
served with aging in wild type and ERβ knock out (ERβKO),
but not in ERαKO, mice after DES (Diethylstilbestrol) treat-
ment. Van Laere et al. demonstrated that activation of NF-
kB in inflammatory breast cancer was associated with loss of
ERα expression, suggesting ERα might play a positive role in
anti-inflammation [56]. In autoimmune encephalomyelitis,
ERα-ligands mediated anti-inflammation is important in
neuroprotection for reducing the levels of central nervous
system inflammation [57]. ERα has been proven to have an
anti-inflammatory function in macrophages. However, the
ERα roles in inflammation-mediated PCa progression may
depend on the ERα location. Our data showed stromal ERα
can decrease macrophage infiltration, but may also suppress
CAF-mediated inflammation response.
Our results showed ERα in CAF not only decreases IL6
expression in CAF cells, but also regulates macrophages
activity to decrease IL6 secretion, although the mecha-
nisms by which CAF.ERα(+) cells affect macrophage
activity are still unclear. Previous studies indicated IL6
and leukemia inhibitory factor (LIF) secretion increases in
tumor tissues can promote TAM generation. Deprivation
of IL6 and LIF can suppress TAM induction. Early studies
indicated that inflammatory cytokines, such as IL6, might
play major roles in the metastasis of breast and neck can-
cers [58, 59]. Michalaki et al. [60] measured serum IL6
concentration from patients and found it is higher in pa-
tients with metastatic disease than localized disease. Lou
et al. [61] also determined IL6 plays an important role in
the PCa metastatic Stat3 signaling transduction pathway.
But, after CAF CM treatment, we found IL6 expression in
PCa cells shows no significant difference between CAF
cells with/without ERα. Hsu et al. also found anti-IL6
might suppress the MMP2 and MMP9 expressions in a
colon cancer model [62]. Importantly, Karin et al. demon-
strated estrogen and propyl pyrazole triol (PPT, ERα spe-
cific agonist) could suppress metastasis of hepatocellular
carcinoma via inhibition of IL6 expression [63]. They also
indicated that the gender difference in tumor susceptibility
resulted from a downregulation of IL6 production by mac-
rophages in response to estrogens.
Conclusion
Current concepts of PCa therapy mainly focus on apply-
ing anti-androgens/blocking AR activity. An increasing
body of studies indicated targeting AR could suppress
PCa growth but promote metastasis. Meanwhile, target-
ing sex hormones with various therapies may have dra-
matic effects, but also result in side effects. In this study,
our results suggest that CAF ERα could be applied as a
Fig. 7 CAF.ERα(+) decreases prostate cancer invasion via diminishing tumor associated macrophage infiltration and IL6 secretion. Schematic
diagram shows that CAF.ERα(+) cells diminishes macrophage recruited toward to PCa via reducing CAF CCL5 secretion. These CAF.ERα(+) cells
reduced invasion of PCa cells are at least partly due to reduced IL6 expression in the macrophages and CAFs
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prognostic marker to predict cancer progression, and
targeting CCL5 and IL6 may be applied as an alternative
therapeutic approach to reduce M2 type macrophage
and PCa invasion in CAF.ERα(−) PCa patients (Fig. 7).
Our study provides candidates, like CCL5 and macro-
phages, for cancer therapy. In the future, we can try to
block the CCL5 signaling pathway to evaluate the possi-
bility of CCL5 in PCa treatment.
Methods
Cell lines
Four PCa cell lines, TRAMP-C1, CWR22Rv-1, C4-2, and
PC-3, and the mouse macrophage cell line, RAW264.7,
were purchased from the American Type Culture Col-
lection (ATCC, Rockville, MD). CAF were prepared as a
primary culture from 36-weeks-old TRAMP mice and
immortalized by SV40 large T-antigen using the detailed
process described previously [24]. All cells were main-
tained in RPMI media with 10 % FBS and 1 % penicillin/
streptomycin.
Isolation and primary culture of macrophages from B6 mice
B6 mice were euthanized by CO2 asphyxiation and
cervical dislocation. After sterilization, femur bones
were isolated and sterilized in 70 % ethanol and rinsed
with PBS. We cut the bones at both ends, flushed the
bone-marrow out with RPMI media with 10 % heat-
inactivated FBS using syringes with 25-gauge needles.
Bone marrow fluid was centrifuged at 1200 x rpm for
10 mins, and cells were cultured with RPMI media
with macrophages colony-stimulating factor (M-CSF
20 ng/ml). After 6 days of culture, primary macrophages
became mature for experimentation.
Lentiviral ERα transduction of CAF cells and firefly
luciferase transduction of CWR22Rv-1 cells
The ERα cDNA was cloned into PmeI site of pWPI len-
tiviral vector. The 293 T packaging cells were transiently
transfected with pMD2.G and psPAX2 with pWPI-
vector or pWPI-ERα, to produce lentiviral particles. The
supernatants containing lentiviral particles were col-
lected 48 h post-transfection of 293 T cells, and poly-
brene was added. The lentiviral supernatants were then
filtered and used to transduce CAF for 48 h. The viral vec-
tor or ERα transduced CAF were then subjected to 5 mg/
L blasticidin selection. To monitor tumor progression by
In vivo Imaging System (IVIS) system, CWR22Rv-1 cells
were tagged with firefly luciferase by lentivirus system.
Migration assay
CAF.ERα(+) or CAF.ERα(−) were cultured in 24-well
plates. After 24 h, macrophages were seeded on the
inserted transwells. After 24 h co-incubation, transwells
were washed with PBS and then fixed by 75 %
ethanol. Next, transwell membranes were stained with
1 % toluidine blue (w/v, prepared in PBS) and non-
migrated macrophages, remaining on the inner trans-
well surface, were wiped off. Macrophages that mi-
grated to the bottom side of membranes were counted
in ten representative areas via microscope (x100 fold).
Invasion assay
Conditioned media (CM) collected from the CAF/macro-
phages co-culture system were used to attract PCa cells
invasion via matrigel coated (0.2 mg/ml, 100 μl, air
dried overnight) transwells. For the co-culture system,
CAF.ERα(+) or CAF.ERα(−) were seeded in the bot-
tom wells of 6-well plates and macrophages were
added into the top transwells (pore size is 0.4 μm).
The CM was collected from bottom wells after 48 h
co-culture. Then, CM was added into each well of
new 24-well plates, then matrigel coated transwells
Table 1 Sequence of qPCR primers
Name Sequence, 5′→ 3′
Ccl2 sense TAA AAA CCT GGA TCG GAA CCA AA
antisense GCA TTA GCT TCA GAT TTA CGG GT
Ccl5 sense TAT CCT GGT GGA GTT GTG
antisense CAG AGT CAT CCC TGC TTC
Cxcl-12 sense TGC ATC AGT GAC GGT AAA CCA
antisense CAC AGT TTG GAG TGT TGAG GAT
IL6 sense CTG CAA GAG ACT TCC ATC CAG
antisense AGT GGT ATA GAC AGG TCT GTT GG
MMP1 sense CCC TGG GAA GCT GTT ATC TTC AA
antisense CGA CCC ACT TCT GAT GGG CT
MMP2 sense ACC TGA ACA CTT TCT ATG GCT G
antisense CTT CCG CAT GGT CTC GAT G
MMP9 sense GGA CCC GAA GCG GAC ATT G
antisense CGT CGT CGA AAT GGG CAT CT
MMP13 sense TGT TTG CAG AGC ACT ACT TGA A
antisense CAG TCA CCT CTAAGCC AAA GAA A
Fizz1 sense CCA ATC CAG CTA ACT ATC CCT CC
antisense ACC CAG TAG CAG TCA TCC CA
Arginase 1 sense TGT CCC TAA TGA CAG CTC CTT
antisense GCA TCC ACC CAA ATG ACA CAT
Ym1 sense CAG GTC TGG CAA TTC TTC TGA A
antisense GTC TTG CTC ATG TGT GTA AGT GA
IL4 sense ATC ATC GGC ATT TTG AAC GAG G
antisense TGC AGC TCC ATG AGA ACA CTA
IL13 sense TGA GCA ACA TCA CAC AAG ACC
antisense GGC CTT GCG GTT ACA GAG G
GAPDH sense AAT GTC ACC GTT GTC CAG TTG
antisense GTG GCT GGG GCT CTA CTT C
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were inserted and PCa cells (TRAMP-C1, CWR22Rv1,
C4-2, or PC-3, as in figures) at 5 × 104/150 μl were
seeded on each transwell. After 24 h incubation,
transwells were washed, fixed, and stained. The
method for counting invaded cell numbers was the
same as with migration assay.
Immunohistochemistry (IHC)
IHC staining was carried out as described previously
[64]. Sections were incubated with the primary anti-
bodies, anti-F4/80 (anti-mouse macrophages, Biolegend,
San Diego, CA), anti-CD206 (anti-M2 macrophage; sc-
20150, Santa Cruz, Dallas, TX), anti-CCL5 (Ameritech
Biomedicines, Houston, TX), anti-IL6 (Abcam, ab6672,
Cambridge, MA) and anti-firefly (Santa Cruz, Dallas,
TX), in 3 % BSA in PBS overnight at 4 °C followed by
respective secondary antibodies.
RNA extraction and quantitative real-time PCR analysis
Total RNA was extracted by Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. RNAs (1 μg) were subjected to reverse transcrip-
tion using Superscript III transcriptase (Invitrogen). The
obtained cDNAs were applied for qPCR using a SYBR
green Bio-Rad CFX96 system. Primers used are listed in
Table 1. Gene mRNA expression levels were normalized
to the mRNA level of GAPDH.
CCL5 promoter luciferase assay
CCL5 promoter luciferase activity was performed using
Lipofectamin 2000 (Invitrogen). CAF cells were trans-
fected with CCL5-Luc (0.4 μg) and 1 ng pRL-TK-Luc re-
porter gene. After transfection, the media were refreshed
to 10 % charcoal/dextran stripped (CD)-FBS media for
24 h and 10 nM E2 was added as indicated for an add-
itional 24 h. Cells were then harvested for the dual lucif-
erase assay kit (Promega, Madison, WI).
ELISA
CM was collected from CAF only or CAF co-cultured
with macrophages for ELISA analyses of CCL5 and IL6
(eBioscience, San Diego, CA) according to the manufac-
turer’s instructions.
Orthotopic implantation
For the orthotopic implantation in mice, CWR22Rv-1
cells were transduced with firefly cDNA (22Rv1-Luc).
CAF were mixed with 22Rv1-Luc cells (1:9 ratio) and
injected into anterior prostate of 8 weeks old athymic
nude mice [24, 41]. For cells injection, 22Rv1-Luc/CAF
cells (9:1 ratio, total 1 × 106) were suspended in 20 μl of
media and Matrigel mix (1:1, v:v). Seven animals were
used per group. Mice were monitored by IVIS every
2 weeks for tracking tumor growth and metastasis by
intraperitoneal injection of luciferin (Gold Biotechnology,
St. Louis, MO) to allow the luciferase to fluoresce. Tu-
mors from primary and metastatic sites were collected
after a final IVIS imaging at 12 weeks after implantation.
Tumor sizes and macrophages infiltration were compared
after IHC staining by macrophage markers. Lymph nodes
were stained with firefly luciferase antibody (Santa Cruz,
c-12) to confirm cancer cells metastasized from the pri-
mary tumor sites. All mice experiments were performed
under a protocol approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of
Rochester Medical Center.
Statistical analysis
Values were expressed as mean ± standard deviation
(S.D.). The Student’s t test was used to calculate two-
sided P values, and considered statistically significant
when P < 0.05.
Additional files
Additional file 1: Figure S1. Stromal E2/ERα signals negatively-regulate
the PCa invasion. CAF.ERα(-) or ERα(+) cells were treated with vehicle, E2
(10 nM) or/and ICI182,780 (10 μM) and co-cultured with macrophages for
48 hr. CMs were collected and added to 24-well plates and the PCa cells
(C4-2) were seeded into inserted transwells pre-coated with matrigel.
After 48 hr of incubation, invaded PCa cells were counted and compared,
and quantitation data is shown below the images.
Additional file 2: Figure S2. CM from co-cultured CAF/macrophages
affects PCa invasion in the 3D culture system. The carton illustrates the
experimental system. CM was collected from co-culture of CAF.ERα(+) or
CAF.ERα(-) cells and RAW264.7 cells or B6 primary macrophages (Mφ) for
24 hr. The CM was then used to treat CWR22Rv-1 cells for 3 days, then
seeded in 3D environment for 12 days to form inter-acinar bridges. (A)
Numbers of inter-aciniar bridges were counted per field and quantifications
are in right panels. (B) Laminin 5 mRNA was quantified to show the invasive
potential of the PCa cells in the 3D culture environment. At Day 12, RNA
was extracted from PCa cells and expression levels of laminin 5 were
measured by qPCR and quantifications are shown. (C) Expression of invasion
related marker, MMP9, was also demonstrated by Q-PCR in CWR22Rv-1 cells
pre-inoculated with the collected CM, quantification is shown. *, P < 0.05 vs.
CM from CAF.ERα(-)/macrophage group.
Additional file 3: Figure S3. Infiltrated Macrophages (Mφ) can affect
the macrophages recruited-related gene profiles in CAF cells. CAF.ERα(-)
or CAF.ERα(+) cells were co-cultured with macrophages for 2 days. We
compared gene profiles of macrophages attraction related CCL5 and IL6
in CAF.ERα(+) and CAF.ERα(-) using qPCR.
Additional file 4: Figure S4. Co-culture of CAF ERα(+) cells and PCa
cells can decrease PCa cell invasion through changing IL-6 expression.
CM was collected from CAF.ERα(-) and CAF.ERα(+) cells together with or
without with IL-6 neutralizing antibody (Anti IL-6) or IgG (control) into
bottom wells of 24-well transwell systems. We then trypsinized and
seeded CWR22Rv-1 and C4-2 cells (1x105) into matrigel-pre-coated
transwells for invasion assay. Quantitation is at right.
Additional file 5: Figure S5. CAF.ERα(+) can reduce the M2 marker
expressions in the co-cultured macrophages (Mφ). (A) ERα in CAF cells
inhibits M2-type macrophages transformation. (B) mRNA expressions of
IL-4 and IL-13 in CAF cells were assayed by qPCR. mRNA expressions of
M2 markers in macrophages were assayed by qPCR. After incubating
with CM collected from CAF.ERα(+) or CAFERα(-), macrophages were
collected to detect M2 markers by qPCR. *, P < 0.05 vs. CAF.ERα(-) cells;
§, P < 0.05 vs. Mφ; δ, p < 0.05 vs. Mφ/CAF.ERα(-) CM.
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